D.A. Davidson & CO. Grows Stake in Johnson & Johnson (JNJ)

D.A. Davidson & CO. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 538,338 shares of the company’s stock after purchasing an additional 2,937 shares during the quarter. Johnson & Johnson comprises 1.4% of D.A. Davidson & CO.’s investment portfolio, making the stock its 6th biggest holding. D.A. Davidson & CO.’s holdings in Johnson & Johnson were worth $69,989,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the company. Rodgers Brothers Inc. lifted its position in Johnson & Johnson by 1.4% in the 3rd quarter. Rodgers Brothers Inc. now owns 67,780 shares of the company’s stock valued at $8,812,000 after acquiring an additional 961 shares in the last quarter. Pinnacle Financial Partners Inc. lifted its position in Johnson & Johnson by 2.8% in the 3rd quarter. Pinnacle Financial Partners Inc. now owns 81,215 shares of the company’s stock valued at $10,559,000 after acquiring an additional 2,177 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Johnson & Johnson by 1.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,068,272 shares of the company’s stock valued at $138,886,000 after acquiring an additional 12,608 shares in the last quarter. Mawer Investment Management Ltd. lifted its position in Johnson & Johnson by 5.3% in the 3rd quarter. Mawer Investment Management Ltd. now owns 1,395,548 shares of the company’s stock valued at $181,423,000 after acquiring an additional 69,818 shares in the last quarter. Finally, Cornerstone Investment Partners LLC lifted its position in Johnson & Johnson by 0.7% in the 3rd quarter. Cornerstone Investment Partners LLC now owns 790,239 shares of the company’s stock valued at $102,739,000 after acquiring an additional 5,234 shares in the last quarter. 65.58% of the stock is currently owned by institutional investors.

Johnson & Johnson (NYSE:JNJ) opened at $132.02 on Friday. Johnson & Johnson has a 1 year low of $120.90 and a 1 year high of $148.32. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. The company has a market cap of $354,670.00, a P/E ratio of 24.31, a price-to-earnings-growth ratio of 2.18 and a beta of 0.74.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, January 23rd. The company reported $1.74 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 27.80%. The firm had revenue of $20.20 billion for the quarter, compared to analysts’ expectations of $20.08 billion. During the same quarter last year, the firm earned $1.58 EPS. The company’s quarterly revenue was up 11.5% compared to the same quarter last year. sell-side analysts forecast that Johnson & Johnson will post 8.11 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 annualized dividend and a dividend yield of 2.55%. Johnson & Johnson’s dividend payout ratio is currently 61.88%.

In other news, VP Paulus Stoffels sold 155,342 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the completion of the sale, the vice president now owns 357,906 shares in the company, valued at approximately $46,477,673.16. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.19% of the company’s stock.

JNJ has been the topic of several recent research reports. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 price target on the stock in a research report on Tuesday, January 23rd. Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the company a “hold” rating in a research report on Monday, January 22nd. Stifel Nicolaus raised their price target on shares of Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a research report on Wednesday, January 24th. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $160.00 price target (up previously from $155.00) on shares of Johnson & Johnson in a research report on Friday, January 12th. Finally, Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, January 9th. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. Johnson & Johnson presently has an average rating of “Hold” and an average target price of $146.16.

COPYRIGHT VIOLATION NOTICE: This article was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://stocknewstimes.com/2018/02/24/d-a-davidson-co-grows-stake-in-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply